$XBI $119.38 +0.1%
Covid Updates
$VALN +3.5% Valneva Signs Purchase Agreement with European Commission for its Inactivated COVID-19 Vaccine VLA2001 source
Pipeline Updates
$GLYC -2.2% Apollomics Inc. Doses First Patient in Phase 3 Clinical Trial in China of GlycoMimetics’ Uproleselan for the Treatment of AML source
$PBYI 0.0% Puma Biotechnology Announces U.S Patent Term Extension for NERLYNX® (neratinib) source
$GILD +0.9% Trodelvy® (sacituzumab govitecan) Granted European Commission Marketing Authorization for Treatment of Metastatic Triple-Negative Breast Cancer in Second Line source
$SCYX +7.4% SCYNEXIS Pivotal Phase 3 VANISH-306 Trial Results Published in the International Journal of Obstetrics and Gynaecology (BJOG) Demonstrate Statistical Superiority of BREXAFEMME® (Ibrexafungerp Tablets) Over Placebo for Vaginal Yeast Infection source
$ORMP -3.9% Oramed Reaches 75% Enrollment in Phase 3 Oral Insulin Study source
$APVO +162.8% Aptevo Therapeutics Reports First Complete Remission, Providing Clinical Update for Its Phase 1b Multi Center, Multi Cohort Expansion Trial in the Treatment of Acute Myeloid Leukemia source
$TNXP +4.9% Tonix Pharmaceuticals Announces FDA Clearance of the IND for Potentiated Intranasal Oxytocin (TNX-1900) for the Prevention of Migraine Headache in Chronic Migraineurs source
Business Updates
$OTLK +5.4% Outlook Therapeutics Announces $10 Million Bought Deal Offering of Common Stock source
$RDHL -0.4% RedHill Biopharma Announces Closing of $15.5 Million Public Offering of American Depositary Shares source
$SLS +3.3% SELLAS Life Sciences Announces Final Court Approval of Settlement of Derivative Litigation source
Posted by JM
Comentários